[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.
Read more The process of discovery and development of a molecule is complex, long and costly. Before making a decision on the offer that best meets your needs, we offer online scientific resources and our latest news to help you get to know us better. Our experts are also at your disposal to help and support you in your research and development program.
Watch this oncology webinar on preclinical pharmacology, covering all step of the drug discovery journey from target validation to clinical studies...
Learn how current in vivo preclinical models meet the needs of microbiome research and innovation while outlining their limitations and the challenges still to be overcome in this growing field.
Learn how to select the most appropriate COVID-19 animal model for preclinical studies in this webinar
Learn how the DRIVE-MRT solution enables the rationalization, design & optimization of targeted & effective radiopharmaceuticals against specific cancers.
There are no resources available for your request. Contact us directly via our contact form for any information request
Find all 4 posters that are presented during AACR 2022. They unveil our expertise in oncology using our scientific know-how (medicinal chemistry, radio-imaging, in vivo model and microbiome)
With small macrocyclic “probes” from our proprietary library in the low nanomolar range IC50, we turned our attention to CDK9 inhibitors with good selectivity profile against CDK1/2/5/7 as a starting point for building bifunctional small macrocyclic kinase degraders.
Use generative AI to generate and identify new PIM-1 kinase inhibitor hits with activity, freedom-to-operate, and good in vitro ADME properties.
NANOCYCLIX® ALK2 INHIBITORS TO OVERCOME CANCER INDUCED ANEMIA
Nanocyclix: next generation kinase therapeuticsA chemocentric approach for the discovery of selective kinase inhibitors
There are no resources available for your request. Contact us directly via our contact form for any information request
Published in Science Advances: the preclinical development program of exoASO-STAT6, a novel, engineered #exosome precision medicine candidate for the treatment of macrophage-rich tumors.
Early/ late resistance marker; Immunological profile; NGS; Non small-cell lung cancer; Pancreatic ductal adenocarcinoma; Triple negative breast or Luminal Breast Cancer.
SARS-CoV-2; antiviral drug combination; hepatitis C virus; hepatitis E virus; human immunodeficiency virus; influenza A virus; interferon-alpha.
SARS-CoV-2; interferon-alpha; nafamostat; antiviral drug combination; broad-spectrum antivirals
SARS-CoV-2; antiviral drug combination; broad-spectrum antivirals; interferon-alpha; nafamostat.
Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors
Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells
In vivo inhibition of RIPK2 kinase alleviates inflammatory disease
There are no resources available for your request. Contact us directly via our contact form for any information request
Read the full press release about our very good results in 2021 & an attractive outlook for 2022 for the group & our BUs Service, Biotech & AI.
Read the full press release about our very good results in 2021 & an attractive outlook for 2022 for the group & our BUs Service, Biotech & AI.
Abzena x Alira Health x Oncodesign: unveil unique integrated solution with specialist services, from biologics discovery to clinical & commercial manufacturing
Read all the details of the collaboration agreement for R&D of a new personalized cancer treatment for aggressive and untreatable tumors.
Read all the details of the collaboration agreement for R&D of a new personalized cancer treatment for aggressive and untreatable tumors.
Find all the 2021 financial information: 2021 turnover of €31.3M, up by 22%, and expects to break even and dive into the BU financial results
Find all the 2021 financial information: 2021 turnover of €31.3M, up by 22%, and expects to break even and dive into the BU financial results
Oncodesign announces all the regulatory dates as far as financial information is concerned. Let's have a look :)
Oncodesign announces all the regulatory dates as far as financial information is concerned. Let's have a look :)
Protection of RIPK2 inhibitors resulting from Nanocyclix® technology with patents granted on the main international markets: Europe, United States, Japan and Eurasia
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.
Discover the alliance of experts in radiopharmaceuticals: an innovative offer in therapeutic development in nuclear medicine from the validation of therapeutic targets, the generation of radiolabeled biological vectors, the optimization of leads, the generation of drug candidates to IND, the design and management of clinical trials.
[Press Release] Explore our brand new service offer DRIVE-MRT. it allows the rationalization, design and optimization of targeted radiopharmaceutical products that are effective against certain metastatic cancers.
Read PRess Release to have an insight on how to organize & leverage healthcare data to accelerate the search for new treatments in oncology using AI.
Hu-PreciMED project will gear French precision medicine industry towards discovering new diagnostic approaches & novel therapeutic treatments.
There are no resources available for your request. Contact us directly via our contact form for any information request
There are no resources available for your request. Contact us directly via our contact form for any information request
There are no resources available for your request. Contact us directly via our contact form for any information request
Come back regularly to check if there is a meeting nearby your place to meet one of our experts in both AI & Drug Discovery.
Check out where to meet Oncodesign this spring... surely we can arrange a meeting somewhere.
Explore the disease & find out about our strategic R&D collaboration with Servier: info, press releases & video!
Read the full press release about our very good results in 2021 & an attractive outlook for 2022 for the group & our BUs Service, Biotech & AI.
Find all 4 posters that are presented during AACR 2022. They unveil our expertise in oncology using our scientific know-how (medicinal chemistry, radio-imaging, in vivo model and microbiome)
Meet us in person at the Annual Meeting of the AACR in New Orleans!
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.
Meet us at the Microbiome & Probiotics congress in San Diego | March 2022. Explore our expertise in assessing the role of microbiome in drug discovery
Abzena x Alira Health x Oncodesign: unveil unique integrated solution with specialist services, from biologics discovery to clinical & commercial manufacturing
Read all the details of the collaboration agreement for R&D of a new personalized cancer treatment for aggressive and untreatable tumors.
Find all the 2021 financial information: 2021 turnover of €31.3M, up by 22%, and expects to break even and dive into the BU financial results
Oncodesign will be at the digital event Microbiome Movement Drug Development. Take the opportunity to learn more about SOLO Microbiome.
Oncodesign announces all the regulatory dates as far as financial information is concerned. Let's have a look :)
Meet Dr. Jan Hoflack during Biotech ShowCase to explore our products pipeline using our technological module Nanocyclix®.
Protection of RIPK2 inhibitors resulting from Nanocyclix® technology with patents granted on the main international markets: Europe, United States, Japan and Eurasia
EHDEN network will enable transparent & fully reproducible research by standardizing both the health data & the analytical pipeline.
Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.
[Webinars] Radiopharmaceutics, COVID-19, Microbiome… join us this fall during a webinar
Oncodesign will be at the in-person event by Oxford Global in London, Discovery UK.
Read all the financial information of Oncodesign and its Business Units Service, Biotech and Artificial Intelligence.
Oncodesign strenghens its Board by appointing Aline Aubertin as new independent director.
Oncodesign Find out how we built our logo! trajectory DNA innovation...green and bleue pharma colors Find out how we built our logo!
Brand new logo for Oncodesign. New graphic identity with evolutive look & feel approach... First element of our new logo.
[Press Release] Find the update of the RIPK2 program and the start of new programs associated with Nanocyclix.
Listen to our expert talk about “preclinical solutions for microbiome investigation in pathological situation and drug development”
Read Press Release the selection of a preclinical candidate resulting from their strategic collaboration to find new treatments for Parkinson’s disease.
Read PRess Release to have an insight on how to organize & leverage healthcare data to accelerate the search for new treatments in oncology using AI.
RoadShow in Japan and South Korean to demonstrate the potency and specificity of our innovative technology module Nanocyclix®
Our brand Oncodesign . Combination of the words oncology and design... Precision Medicine for patient... Oncodesign
There are no resources available for your request. Contact us directly via our contact form for any information request